Vysis

Vysis develops, commercializes, and sells clinical products that provide critical information for the assessment and management of cancer, prenatal disorders, and other genetic diseases. The company has assembled a management team with extensive experience in the development, commercialization, and sale of DNA-based diagnostic products and related genetic workstations. Vysis was the first company to receive FDA clearance for a genomic product using fluorescence in situ hybridization (FISH) technology. Currently, Vysis sells over 240 research products through its direct sales operations in the U.S. and Europe, as well as a global sales network covering 28 countries, and markets four FDA-approved clinical products. It has installed more than 320 proprietary genetic workstations in 224 laboratories across 18 countries. The company is developing nine clinical products and has expanded its leading portfolio of clinical offerings through collaborations with top medical research institutions, including the University of California, San Francisco, Mayo Clinic, St. Jude Children's Research Hospital, the University of Chicago, and the Institute for Reproductive Genetics.